Maryam Valapour

Maryam Valapour

Auto-generated profile, based on publicly available information

Maryam Valapour

Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
MVMaryam Valapour
Maryam Valapour
CLCarli J. Lehr
Carli J. Lehr
AWAndrew Wey
Andrew Wey
MSMelissa A. Skeans
Melissa A. Skeans
JMJonathan Miller
Jonathan Miller
ELErika D. Lease
Erika D. Lease
Efforts are underway to transition the current lung allocation system to a continuous distribution framework whereby multiple factors are simultaneously combined into a Composite Allocation Score (CAS) to prioritize candidates for lung transplant. The purpose of this study was to compare discrete CAS scenarios with the current concentric circle-based allocation system to assess their potential effects on the US lung transplantation system using the Scientific Registry of Transplant Recipients' thoracic simulated allocation model. Six alternative CAS scenarios were compared over 10 simulation runs using data from individuals on the lung transplant waiting list from January 1, 2018, through December 31, 2019. Outcome measures were transplant rate, count, waitlist deaths, posttransplant deaths within 2 years, donor-to-recipient distance, and percentage of organs predicted to have flown. Across scenarios, waitlist deaths decreased by 36% to 47%, with larger decreases in deaths at lower placement efficiency weight and higher weighting of the waitlist outcomes. When waitlist outcomes were equally weighted to posttransplant outcomes, more transplants occurred in individuals with the highest expected posttransplant survival. All CAS scenarios led to improved overall measures of equity compared with the current Lung Allocation Score system, including reduced waitlist deaths, and resulted in similar posttransplant survival.

18 December 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MTMatthew Triplette
Matthew Triplette
KCKristina Crothers
Kristina Crothers
PMParag Mahale
Parag Mahale
EYElizabeth L. Yanik
Elizabeth L. Yanik
MVMaryam Valapour
Maryam Valapour
EEEric A. Engels
Eric A. Engels
Lung transplant recipients have an increased risk of lung cancer that is poorly understood. Prior studies are largely descriptive and single‐center, and have not examined risk factors or outcomes in this population. This registry‐linkage study utilized matched transplant and cancer registry data from 17 US states/regions during 1987‐2012. We used standardized incidence ratios (SIRs) to compare incidence with the general population, Poisson models to identify lung cancer risk factors, and Cox models to compare survival after diagnosis. Lung cancer risk was increased among lung recipients (SIR 4.8, 95% confidence interval [CI] 4.1‐5.5). Those with single lung transplant had 13‐fold (95% CI 11‐15) increased risk in the native lung. Native lung cancer risk factors included age, prior smoking, time since transplant, and idiopathic pulmonary fibrosis. Compared with cases in the general population, lung cancers in recipients were more frequently localized stage (P = .02) and treated surgically (P = .05). However, recipients had higher all‐cause (adjusted hazard ratio 1.90, 95% CI 1.52‐2.37) and cancer‐specific mortality (adjusted hazard ratio 1.67, 95% CI 1.28‐2.18). In conclusion, lung cancer risk is increased after lung transplant, especially in the native lung of single lung recipients. Traditional risk factors are associated with lung cancer in these patients. Lung cancer survival is worse among lung recipients despite earlier diagnosis.

1 April 2020 in Chest
Verified
Journal Article
Closed access
CLCarli J. Lehr
Carli J. Lehr
EBEugene H. Blackstone
Eugene H. Blackstone
KMKenneth R. McCurry
Kenneth R. McCurry
LTLucy Thuita
Lucy Thuita
WTWayne M. Tsuang
Wayne M. Tsuang
MVMaryam Valapour
Maryam Valapour

23 April 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
KRKathleen J. Ramos
Kathleen J. Ramos
JGJennifer Guimbellot
Jennifer Guimbellot
MVMaryam Valapour
Maryam Valapour
LBLauren E. Bartlett
Lauren E. Bartlett
TWTravis Hee Wai
Travis Hee Wai
JDJoshua M. Diamond
Joshua M. Diamond

15 October 2019 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CLCarli J. Lehr
Carli J. Lehr
MSMelissa Skeans
Melissa Skeans
EDElliott Dasenbrook
Elliott Dasenbrook
AFAliza Fink
Aliza Fink
GFGabriela Fernandez
Gabriela Fernandez
MVMaryam Valapour
Maryam Valapour
Rationale: Clinical variables associated with shortened survival in patients with advanced-stage cystic fibrosis (CF) are not included in the lung allocation score (LAS). Objectives: To identify variables associated with wait-list and post-transplant mortality for CF lung transplant candidates using a novel database and to analyze the impact of including new CF-specific variables in the LAS system. Methods: A deterministic matching algorithm identified patients from the Scientific Registry of Transplant Recipients and the Cystic Fibrosis Foundation Patient Registry. LAS wait-list and post-transplant survival models were recalculated using CF-specific variables. This multicenter, retrospective, population-based study of all lung transplant wait-list candidates aged 12 years or older from January 1, 2011, to December 31, 2014, included 9,043 patients on the lung transplant waiting list and 6,110 lung transplant recipients between 2011 and 2014, comprising 1,020 and 677 with CF, respectively. Measurements and Main Results: Measured outcomes were changes in LAS and lung allocation rank. For CF candidates, any Burkholderia sp. (hazard ratio [HR], 2.8; 95% confidence interval [CI], 1.2–6.6), 29–42 days hospitalized (HR 2.8; CI 1.3–5.9), massive hemoptysis (HR 2.1; CI 1.1–3.9), and relative drop in FEV1 ≥30% over 12 months (HR 1.7; CI 1.0–2.8) increased wait-list mortality risk; pulmonary exacerbation time 15–28 days (1.8; 1.1–2.9) increased post-transplant mortality risk. A relative drop in FEV1 ≥10% in chronic obstructive pulmonary disease (COPD) candidates was associated with increased wait-list mortality risk (HR 2.6; CI 1.2–5.4). Variability in LAS score and rank increased in patients with CF. Priority for transplant increased for COPD candidates. Access did not change for other diagnosis groups. Conclusions: Adding CF-specific variables improved discrimination among wait-listed CF candidates and benefited COPD candidates.

1 November 2020 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
CLCarli J. Lehr
Carli J. Lehr
AFAliza K. Fink
Aliza K. Fink
MSMelissa Skeans
Melissa Skeans
AFAlbert Faro
Albert Faro
GFGabriela Fernandez
Gabriela Fernandez
MVMaryam Valapour
Maryam Valapour
Rationale: Referrals for lung transplant and transplant rates in the United States are lower than in Canada for patients with advanced cystic fibrosis (CF) lung disease. Further study of factors limiting access are needed to optimize referral and transplant for this population. Objectives: To determine the effect of socioeconomic position, while accounting for disease severity, on the likelihood of wait-listing for lung transplant in the United States. Methods: A case–control study of 3,110 patients (1,555 wait-listed, 1,555 never wait-listed) in the linked CF Foundation Patient Registry/Scientific Registry of Transplant Recipients was performed with 1:1 matching for age, forced expiratory volume in 1 second, and year. Logistic regression was performed with univariate and multivariate analyses accounting for eight clinical factors (sex, oxygen use, body mass index, hemoptysis, forced vital capacity, methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa, and i.v. antibiotic days) and six socioeconomic factors (race, marital status, education, health insurance, median zip code income, and distance to transplant program). The CF Health Score and Socioeconomic Barrier Score were created based on summation of variables. Interactions between scores were calculated. Results: We found an inverse relationship between the probability of wait-listing and CF Health Score and Socioeconomic Barrier Score. As the CF Health Score decreased (less healthy), the probability of wait-listing increased by 69.3% from a score of 7 to 2. As the Socioeconomic Barrier Score decreased (fewer barriers), the probability of wait-listing increased by 31.7% from a score of ≥5 to 1). Regardless of illness severity, socioeconomic barriers presented an impediment to wait-listing. Individuals with higher Socioeconomic Barrier Scores accessed transplant about half as often as those with lower scores at the same level of medical severity. Analysis of interactions demonstrated a higher probability of wait-listing for individuals with moderate health severity and fewer social barriers compared with sicker individuals with more socioeconomic barriers. Conclusions: Accrual of socioeconomic barriers limits access to lung transplant irrespective of disease severity, a finding of substantial concern for patients with CF and for transplant providers. Future interventions can focus on this at-risk population early in the disease course.